➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,989,494

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,989,494 protect, and when does it expire?

Patent 7,989,494 protects FARYDAK and is included in one NDA.

This patent has forty-three patent family members in thirty-one countries.

Summary for Patent: 7,989,494
Title:Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E- -2-propenamide
Abstract: Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E- -2-propenamide free base and salts thereof are prepared by various processes.
Inventor(s): Acemoglu; Murat (Basel, CH), Bajwa; Joginder S. (Elmwood Park, NJ), Karpinski; Piotr (Lincoln Park, NJ), Papoutsakis; Dimitris (Acton, MA), Slade; Joel (Flanders, NJ), Stowasser; Frank (Murg, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:12/302,564
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,989,494
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,989,494

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,989,494

PCT Information
PCT FiledJune 07, 2007PCT Application Number:PCT/US2007/070561
PCT Publication Date:December 21, 2007PCT Publication Number: WO2007/146716

International Family Members for US Patent 7,989,494

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 061297   Start Trial
Australia 2007257881   Start Trial
Brazil PI0712993   Start Trial
Canada 2650263   Start Trial
Chile 2007001689   Start Trial
China 101641328   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.